OmniAb, Inc.
NASDAQOABI dropped 11.6% on October 6 to close at $4.35, a sharp single-day move that arrived the same morning two analysts raised their price targets, creating one of the starker divergences between Street conviction and market action seen in small-cap biotech this week. The analyst moves are the clearest signal worth examining. Leerink Partners raised its target from $10 to $12…
OABI cost to borrow surges to 2.13%, up 261% in one week as short-selling demand intensifies.
Snapshot as of 18 Oct 2026
OABI dropped 11.6% on October 6 to close at $4.35, a sharp single-day move that arrived the same morning two analysts raised their price targets, creating one of the starker divergences between Street conviction and…
OABI enters September at a fragile junction — a stock that nearly doubled in a month now faces growing short-side pressure and a cost-to-borrow spike, even as the analyst consensus remains firmly bullish. The most…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for OABI — free to start on ORTEX.
Sign up for free →Open OABI on ORTEX